Biomerieux - Public Comps and Valuation Multiples

Biomerieux Overview

About Biomerieux

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.

Founded

1967

HQ

Employees

14.8K+

Website

biomerieux.com

Sectors

Laboratory Services
Medical Imaging & Diagnostics
BioTech
HealthTech

Financials

LTM Revenue $4.8B

LTM EBITDA $1.2B

EV

$15.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Biomerieux Financials

As of September 2025, Biomerieux reported last 12-month revenue of $4.8B and EBITDA of $1.2B.

In the same period, Biomerieux generated $2.7B in LTM gross profit and $550M in net income.

See Biomerieux valuation multiples based on analyst estimates

Biomerieux P&L

In the most recent fiscal year, Biomerieux reported revenue of $4.6B and EBITDA of $1.0B.

Biomerieux expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Biomerieux valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$4.8B	XXX	$4.6B	XXX	XXX	XXX
Gross Profit	$2.7B	XXX	$2.6B	XXX	XXX	XXX
Gross Margin	57%	XXX	56%	XXX	XXX	XXX
EBITDA	$1.2B	XXX	$1.0B	XXX	XXX	XXX
EBITDA Margin	24%	XXX	23%	XXX	XXX	XXX
EBIT	$775M	XXX	$738M	XXX	XXX	XXX
EBIT Margin	16%	XXX	16%	XXX	XXX	XXX
Net Profit	$550M	XXX	$500M	XXX	XXX	XXX
Net Margin	12%	XXX	11%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Biomerieux including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $4.8B. EBITDA for the last twelve months was $1.2B. In the most recent fiscal year, Biomerieux achieved $4.6B in revenue and $1.0B in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$4.8B	Analyst estimates available to subscribers	$4.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$2.7B	Analyst estimates available to subscribers	$2.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	56.9% gross margin	Analyst estimates available to subscribers	55.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$1.2B	Analyst estimates available to subscribers	$1.0B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	24.4% EBITDA margin	Analyst estimates available to subscribers	22.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$775M	Analyst estimates available to subscribers	$738M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	16.2% EBIT margin	Analyst estimates available to subscribers	16.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$550M	Analyst estimates available to subscribers	$500M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	11.5% net profit margin	Analyst estimates available to subscribers	10.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Biomerieux

This financial data table provides comprehensive performance metrics for Biomerieux, a company based in France. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Biomerieux generated $4.8B in revenue over the last twelve months.
The company achieved $1.2B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $2.7B.
Net income over the last twelve months reached $550M.

Fiscal Year Performance

In the most recent fiscal year, Biomerieux reported $4.6B in total revenue.
Fiscal year EBITDA was $1.0B.
The company maintained a gross profit margin of 55.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 22.6%.
Net profit margin reached 10.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Biomerieux. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Biomerieux Stock Performance

Biomerieux has current market cap of EUR 13.0B (or $15.1B), and EV of EUR 13.1B (or $15.2B).

Market Cap Evolution

Biomerieux Stock Data

As of October 17, 2025, Biomerieux's stock price is EUR 110 (or $128).

See Biomerieux trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$15.2B	$15.1B	XXX	XXX	XXX	XXX	$4.98

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Biomerieux Valuation Multiples

Biomerieux's trades at 3.3x EV/Revenue multiple, and 14.7x EV/EBITDA.

See valuation multiples for Biomerieux and 15K+ public comps

Biomerieux Financial Valuation Multiples

As of October 17, 2025, Biomerieux has market cap of $15.1B and EV of $15.2B.

Equity research analysts estimate Biomerieux's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Biomerieux has a P/E ratio of 27.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$15.1B	XXX	$15.1B	XXX	XXX	XXX
EV (current)	$15.2B	XXX	$15.2B	XXX	XXX	XXX
EV/Revenue	3.2x	XXX	3.3x	XXX	XXX	XXX
EV/EBITDA	13.0x	XXX	14.7x	XXX	XXX	XXX
EV/EBIT	19.6x	XXX	20.6x	XXX	XXX	XXX
EV/Gross Profit	5.6x	XXX	n/a	XXX	XXX	XXX
P/E	27.4x	XXX	30.1x	XXX	XXX	XXX
EV/FCF	25.1x	XXX	40.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Biomerieux Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Biomerieux Margins & Growth Rates

Biomerieux's last 12 month revenue growth is 6%

Biomerieux's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Biomerieux's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Biomerieux's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Biomerieux and other 15K+ public comps

Biomerieux Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	6%	XXX	6%	XXX	XXX	XXX
EBITDA Margin	24%	XXX	23%	XXX	XXX	XXX
EBITDA Growth	10%	XXX	21%	XXX	XXX	XXX
Rule of 40	25%	XXX	29%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	40%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	20%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	12%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	40%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial